Immunologix boosts Translational Sciences division with new recruits

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/MarkusBlanke)
(Image: Getty/MarkusBlanke)

Related tags: immunologix, translational sciences, Bioanalytical, Biomarker, Biogen

Immunologix bolsters its scientific expertise with two new hires to build on its bioanalytical biomarker programs created from the launch of its Translational Sciences division.

Led by former senior director and head of development biomarkers and bioanalytical services at Biogen, Lauren Stevenson, the newly added Translational Sciences division will provide resources to advise, develop, and implement integrated strategies and solutions for development programs.

Devangi Mehta, a former director of development biomarkers and bioanalytical sciences, also at Biogen, will join Stevenson in establishing strategies for the new division’s clients.

Stevenson said in a statement that together she and Mehta will work together with the team to “pioneer a new model of scientific support.”

Mehta and Stevenson will join the VP of Biomarker Services at Immunologix, John Allinson, in leading the team. Both Stevenson and Immunologix president and CEO Michael Anderson said in their statements that combination of experience of the new team will provide diverse insights to the division’s scientific services for the bioanalytical lab industry.

Immunologix has previously worked with companies like DavosPharma and GenScript for biopharmaceutical development services.

In 2011, DavosPharma and Immunologix​ teamed up to provide the latter with access to technology for the production of antigen-targeting human monoclonal antibodies for clinical trials.

Contract research organization GenScript also tapped Immunologix​ for therapeutic antibody production technologies.

Related news

Related products

show more

Shifting the Biomanufacturing Paradigm

Shifting the Biomanufacturing Paradigm

Take the Right Path Upstream with MilliporeSigma | 12-May-2020 | Technical / White Paper

The first commercial monoclonal antibody (mAb) was approved in 1986 and today, the global market is large and growing. Reports estimate the size of the...

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Related suppliers

Follow us

Products

View more

Webinars